Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

Autor: Yves Coppieters, Félicien Ilunga-Ilunga, Daniel Muteba, Paul Mansiangi, Jean-Claude Makenga Bof
Rok vydání: 2019
Předmět:
Adult
Male
myalgia
Population
Pharmacologie
Onchocerciasis
Santé publique
030226 pharmacology & pharmacy
03 medical and health sciences
0302 clinical medicine
Ivermectin
lcsh:RA1190-1270
Community-directed treatment with ivermectin
Environmental health
Ivermectin -- adverse effects -- therapeutic use
parasitic diseases
medicine
Humans
Pharmacology (medical)
Adverse effect
education
lcsh:Toxicology. Poisons
Retrospective Studies
Pharmacology
Community based
education.field_of_study
business.industry
Communities
lcsh:RM1-950
Retrospective cohort study
Epidémiologie
Democratic Republic of Congo
medicine.disease
Severe adverse effects
Filaricides
lcsh:Therapeutics. Pharmacology
Onchocerciasis -- drug therapy
Community Medicine
Democratic Republic of the Congo
Female
medicine.symptom
Headaches
business
Research Article
Filaricides -- adverse effects -- therapeutic use
medicine.drug
Zdroj: BMC Pharmacology and Toxicology, 20 (1
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
BMC Pharmacology & Toxicology
ISSN: 2050-6511
DOI: 10.1186/s40360-019-0327-5
Popis: The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the frequency of post-CDTI SAE as well as factors associated with the occurrence of SAE.
SCOPUS: ar.j
info:eu-repo/semantics/published
Databáze: OpenAIRE
Externí odkaz: